Open Access

A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report

  • Authors:
    • Shota Igaue
    • Takayuki Okuno
    • Hajime Ishibashi
    • Masaru Nemoto
    • Masaya Hiyoshi
    • Hiroshi Kawasaki
    • Hitoaki Saitoh
    • Makoto Saitoh
    • Kiwamu Akagi
    • Junji Yamamoto
  • View Affiliations

  • Published online on: May 17, 2022     https://doi.org/10.3892/ol.2022.13332
  • Article Number: 211
  • Copyright: © Igaue et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The standard treatment for colorectal cancer has always been surgery and chemotherapy, which may be used in combination to treat patients. Immune checkpoint inhibitors have been a significant advancement in the standard treatment of metastatic, unresectable colorectal cancer with deficient mismatch repair. However, little information is available about their use in neoadjuvant and conversion settings with only a few case reports and only one phase 2 trial. The present study reports the case of a large, locally advanced right‑sided metastatic deficient mismatch repair/microsatellite instability‑high colon cancer, which showed a pathological complete response after combination treatment with nivolumab and ipilimumab. To the best of our knowledge, resected metastatic colon cancer with a pathological complete response after treatment using dual immune checkpoint inhibitors has not been previously reported. Overall, this case report suggests the use of immune checkpoint inhibitors before colorectal surgery.
View Figures
View References

Related Articles

Journal Cover

July-2022
Volume 24 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Igaue S, Okuno T, Ishibashi H, Nemoto M, Hiyoshi M, Kawasaki H, Saitoh H, Saitoh M, Akagi K, Yamamoto J, Yamamoto J, et al: A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report. Oncol Lett 24: 211, 2022
APA
Igaue, S., Okuno, T., Ishibashi, H., Nemoto, M., Hiyoshi, M., Kawasaki, H. ... Yamamoto, J. (2022). A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report. Oncology Letters, 24, 211. https://doi.org/10.3892/ol.2022.13332
MLA
Igaue, S., Okuno, T., Ishibashi, H., Nemoto, M., Hiyoshi, M., Kawasaki, H., Saitoh, H., Saitoh, M., Akagi, K., Yamamoto, J."A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report". Oncology Letters 24.1 (2022): 211.
Chicago
Igaue, S., Okuno, T., Ishibashi, H., Nemoto, M., Hiyoshi, M., Kawasaki, H., Saitoh, H., Saitoh, M., Akagi, K., Yamamoto, J."A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report". Oncology Letters 24, no. 1 (2022): 211. https://doi.org/10.3892/ol.2022.13332